Aaron Robertson

Aaron Robertson

Auto-generated profile, based on publicly available information

Aaron Robertson

Division of Otolaryngology—Head & Neck Surgery, Department of Surgery, University of Wisconsin-Madison, Madison, WI, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 December 2020 in Journal of Bone and Joint Surgery
Verified
Journal Article
Closed access
JAJulie Agel
Julie Agel
ARAaron J. Robertson
Aaron J. Robertson
ANAvrey A. Novak
Avrey A. Novak
JHJonah Hebert-Davies
Jonah Hebert-Davies
CKConor P. Kleweno
Conor P. Kleweno
Update: This article was updated on April 15, 2021, because of a previous error. On page 474, in Table V, the row that had read “Distance (mi)” now reads “Distance* (mi).” An erratum has been published: J Bone Joint Surg Am. 2021 May 19;103(10):e44. Background: Clinical follow-up in orthopaedic trauma is challenging, yet expectations exist that a 1-year follow-up is the minimum requirement for clinical trials and research publications. The primary purpose of our study was to evaluate the rate of follow-up after operative orthopaedic trauma care and the relationship to clinical care. Our secondary aim was to identify any independent risk factors regarding follow-up completion. Methods: A chart review of patients operatively treated for a traumatic injury during the months of January and July 2016 was conducted. Patient demographic characteristics, injury type, severity, and patient distance from the hospital were collected. The final clinical instructions and whether a return visit was requested or as needed were recorded. Results: There were 293 patients in this study, of whom 84 (29%) had follow-up of at least 1 year and 52 (18%) were instructed to follow up only as needed at their last visit prior to the 1-year mark. When removing the latter 52 patients, the 1-year follow-up rate was 35% (84 of 241 patients). Of these 241 patients, 157 (65%) were requested to return for additional clinical care but failed to return prior to 1 year. Logistic regression identified tobacco use (odds ratio [OR], 0.34 [95% confidence interval (CI), 0.15 to 0.77]; p = 0.010), final appointment status (OR, 6.3 [95% CI, 3.4 to 11.6]; p < 0.001), isolated compared with multiple fractures (OR, 2.2 [95% CI, 1.2 to 4.1]; p = 0.013), and distance from the trauma center per mile as a continuous variable (OR, 0.999 [95% CI, 0.998 to 1.0]; p = 0.03) as significant predictors. Conclusions: Our data suggest that a 1-year clinic follow-up requirement may not be feasible. We observed a low rate of patients with a minimum 1-year clinical follow-up. Clinical care had been completed in 18% of patients prior to 1 year. Journal and grant reviewers may need to consider the feasibility and clinical relevance of these follow-up expectations.

1 June 2017 in The Journal of Hand Surgery
Verified
Journal Article
Closed access
BLBrian C. Lau
Brian C. Lau
ARAaron Robertson
Aaron Robertson
DMDaria Motamedi
Daria Motamedi
NLNicolas Lee
Nicolas Lee

26 April 2025 in Annals of Otology, Rhinology & Laryngology
Verified
Journal Article
Closed access
NNNainika Nanda
Nainika Nanda
ARAaron Robertson
Aaron Robertson
DUDavid C. Upton
David C. Upton
Introduction: Mandibular advancement devices (MADs) are a treatment option for obstructive sleep apnea/hypopnea syndrome (OSAHS); however, the ideal patient selection criteria continue to be refined. Objectives: To determine the overall efficacy of a custom titratable MAD in treating a subset of OSAHS patients. A secondary objective was to determine predictive factors affecting treatment outcome for MAD therapy. Methods: Retrospective analysis of a single otolaryngologist’s (DCU) experience in 86 patients with Friedman Stages 2 to 4 treated with a MAD (Thornton Adjustable Positioner) at an academic medical center. Results: Therapeutic success as measured by type 3 home apnea test (HSAT) before and after proper MAD titration was defined as a 50% reduction in initial AHI or reduction of AHI to a mild severity below 15 events/hour. The 50% AHI reduction rate after MAD titration was 64% and the overall success rate inclusive of patients with reduction below 15 events/hour was 72.1%. MAD therapy significantly reduced the mean AHI (−10.4 ± 12.6), P < .001) and improved the minimum oxygen saturation (1.88 ± 5.79, P = .003). Significant reduction of OSAHS severity was seen across all treatment groups regardless of initial OSAHS severity: mild (55.9%), moderate (85%), severe (75%; P < .001 for all 3 groups). High BMI, advanced age, concentric velopharyngeal collapse pattern, prior pharyngeal surgery, and male sex were not statistically significant predictors of ineffectiveness. Conclusions: MAD therapy for OSAHS in patients with Friedman Stages 2 to 4 is an effective treatment in 72% of cases and should be considered as an initial treatment option within this subset of patients, inclusive of those with initially severe, moderate, and mild OSAHS.